Literature DB >> 26324236

MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α.

Chunyan Li1, Yulin Wang2, Shuming Lu1, Zhuqing Zhang3, Hua Meng1, Lina Liang1, Yan Zhang1, Bo Song4.   

Abstract

The microRNA (miRNA), miR‑34a is significant in colon cancer progression. In the present study, the role of miR‑34a in colon cancer cell proliferation and metastasis was investigated. It was found that the expression of miR‑34a in colon cancer tissues and cell lines was lower when compared with that of normal tissues and cells. Further research demonstrated that miR‑34a inhibited cell proliferation, induced G1 phase arrest, and suppressed metastasis and epithelial mesenchymal transition in colon cancer cells. Bioinformatic prediction indicated that platelet‑derived growth factor receptor α (PDGFRA) was a potential target gene of miR‑34a and a luciferase assay identified that PDGFRA was a novel direct target gene of miR‑34a. In addition, assays of western blot analyses and quantitative reverse‑transcription polymerase chain reaction confirmed that miR‑34a decreased PDGFRA mRNA expression and protein levels in colon cancer cells. Assessment of cellular function indicated that miR‑34a inhibited colon cancer progression via PDGFRA. These findings demonstrate that miR‑34a may act as a negative regulator in colon cancer by targeting PDGFRA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324236     DOI: 10.3892/mmr.2015.4263

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  12 in total

1.  Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.

Authors:  Po-Chen Chu; Peng-Chan Lin; Hsing-Yu Wu; Kuen-Tyng Lin; Christina Wu; Tanios Bekaii-Saab; Yih-Jyh Lin; Chung-Ta Lee; Jeng-Chang Lee; Ching-Shih Chen
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

Review 2.  Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.

Authors:  Giuseppe Badalamenti; Carlo Messina; Ida De Luca; Emmanuela Musso; Alessandra Casarin; Lorena Incorvaia
Journal:  Radiol Med       Date:  2018-04-04       Impact factor: 3.469

Review 3.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

Review 4.  MiRNAs in β-Cell Development, Identity, and Disease.

Authors:  Aida Martinez-Sanchez; Guy A Rutter; Mathieu Latreille
Journal:  Front Genet       Date:  2017-01-11       Impact factor: 4.599

5.  Network analysis based on TCGA reveals hub genes in colon cancer.

Authors:  Fenzan Wu; Guoping Yuan; Junjie Chen; Chengzu Wang
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

Review 6.  Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.

Authors:  Alexandra Pender; Robin L Jones
Journal:  Clin Pharmacol       Date:  2017-12-04

Review 7.  Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets.

Authors:  Jingmei Lin; Chia-Chen Chuang; Li Zuo
Journal:  Oncotarget       Date:  2017-03-07

Review 8.  Relevance of MicroRNAs as Potential Diagnostic and Prognostic Markers in Colorectal Cancer.

Authors:  Grzegorz Hibner; Małgorzata Kimsa-Furdzik; Tomasz Francuz
Journal:  Int J Mol Sci       Date:  2018-09-27       Impact factor: 5.923

9.  miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells.

Authors:  Yong Li; Ping Gong; Ji-Xue Hou; Wei Huang; Xiao-Ping Ma; Yu-Li Wang; Jing Li; Xiao-Bin Cui; Na Li
Journal:  J Immunol Res       Date:  2018-08-02       Impact factor: 4.818

10.  Upregulation of microRNA-383 inhibits the proliferation, migration and invasion of colon cancer cells.

Authors:  Ying Cui; Le-Gao Chen; Hai-Bo Yao; Jun Zhang; Ke-Feng Ding
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.